Detalhe da pesquisa
1.
Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported Outcomes.
Cerebellum
; 22(6): 1257-1273, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495470
2.
A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
Cephalalgia
; 43(6): 3331024231179131, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37282507
3.
Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
Cephalalgia
; 43(2): 3331024221141686, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739511
4.
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Lancet
; 397(10268): 51-60, 2021 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33338437
5.
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
N Engl J Med
; 381(2): 142-149, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31291516
6.
Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States.
Headache
; 62(4): 473-481, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35343590
7.
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Headache
; 62(9): 1153-1163, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239038
8.
A stated preference survey to explore patient preferences for novel preventive migraine treatments.
Headache
; 62(9): 1187-1197, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36047857
9.
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).
J Headache Pain
; 23(1): 10, 2022 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038983
10.
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study.
J Headache Pain
; 23(1): 65, 2022 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35676636
11.
Measuring interictal burden among people affected by migraine: a descriptive survey study.
J Headache Pain
; 23(1): 97, 2022 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35941572
12.
Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Headache
; 61(6): 906-915, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34021585
13.
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Lancet
; 394(10200): 737-745, 2019 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31311674
14.
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Headache
; 60(8): 1734-1742, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32799325
15.
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture.
PLoS Genet
; 9(10): e1003864, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24204291
16.
Efficacy of combining interview techniques in detecting deception related to bio-threat issues.
Behav Sci Law
; 32(3): 269-85, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24549687
17.
Video-Based Kinematic Analysis of Movement Quality in a Phase 3 Clinical Trial of Troriluzole in Adults with Spinocerebellar Ataxia: A Post Hoc Analysis.
Neurol Ther
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38814532
18.
Long-term outcome in adults with obsessive-compulsive disorder.
Depress Anxiety
; 30(8): 716-22, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23532944
19.
Sheehan Suicidality Tracking Scale (S-STS): reliability, convergent and discriminative validity in young Italian adults.
Compr Psychiatry
; 54(7): 842-9, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23618606
20.
Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group Study.
Clin Pharmacol Drug Dev
; 12(8): 790-800, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37073443